ArticleDiabetes, metabolic syndrome and obesity : targets and therapy2025
Relationship Between α-Glucosidase Inhibitors Application and Bone Mineral Density in Chinese Patients with Type 2 Diabetes Mellitus: A Cross-Sectional Study.
Article in Diabetes, metabolic syndrome and obesity : targets and therapy, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Purpose: To investigate the correlation between α-glycosidase inhibitors (AGIs) and bone mineral density (BMD) in patients with type 2 diabetes mellitus (T2DM). Patients and Methods: A total of 251 patients with T2DM admitted to the Zhongshan Hospital, Fudan University (Xiamen Branch) from September 2018 to September 2020 were enrolled. Baseline information of patients was analyzed according to different BMD subgroups. Clinical characteristics and BMD were compared between AGIs Group (n = 58) and non-AGIs group (n = 193). Multiple linear regression model was used to examine the relationship between AGIs application and BMD. Results: The lower BMD group showed the characteristics of older age, longer duration of diabetes, lower body mass index (BMI) and estradiol (E2). In the AGIs group, the proportion of females, duration of diabetes, incidence of diabetic peripheral vascular disease and the use of sulfonylureas were significantly higher than those in the non-AGIs group (p < 0.05), the results of HbA1c, TC, TG, LDL, FT3, FT4 were opposite (p < 0.05). Compared with the non-AGIs group, the BMD of femoral neck and lumbar spine in the AGIs group was significantly decreased, FRAX score and the prevalence of osteoporosis were remarkably increased, accompanied by a decrease in β-CTX and P1NP level. Multivariate linear regression analysis showed a significant negative correlation between AGIs and lumbar BMD after adjustment for potential confounding variables (β = -0.053, 95% CI -0.100~0.006, P = 0.029). Conclusion: This study indicates that the use of AGIs in patients with T2DM is significantly associated with an increased risk of BMD decline, osteoporosis, and fracture.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.